Clinical Trials

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary objectives of the Registry are: * To enhance the understanding of the variability, progression, and natural history of Fabry disease, including heterozygous females with the disease; * To assist the Fabry medical community with the development of recommendations for monitoring patients and reports on patient outcomes to help optimize patient care; * To characterize and describe the Fabry population as a whole; * To evaluate the long-term safety and effectiveness of Fabrazyme® Fabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Fabry Registry, regardless of whether she is receiving disease-specific therapy (such as enzyme replacement therapy with agalsidase beta) and irrespective of the commercial product with which she may be treated. Data from the Sub-registry are also used to fulfill various global regulatory requirements, to support product development/reimbursement, and for other research and non-research-related purposes. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician. If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

Review the workflow of updating the Milestone Dollars on Patient Event Milestones and the effect on Financial Reporting data.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

test new velos insert 06_23_2025

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

test velos inser abstract 6_23_25 2

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

test ctms only PI update

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

Velos project with PIVelos project with PI

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

test ctms only iris insert

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

Test Protocol ChangeTest Protocol Change

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

Velos Only test 06242025Velos Only test 06242025Velos Only test 06242025

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent). Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Intravesical BCG is a solution containing the live BCG bacteria that is placed in the bladder via a catheter (intravesical). When the solution comes into direct contact with the bladder wall, it stimulates the body's immune system which kills tumor cells. Giving gemcitabine with intravesical BCG may kill more tumor cells in patients with recurrent non-muscle invasive bladder cancer.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449